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Abstract
Background: Shiga toxin-producing E. coli (STEC) infection is associated with haemolytic uremic syndrome (HUS).
Therefore Norway has implemented strict guidelines for prevention and control of STEC infection. However, only a
subgroup of STEC leads to HUS. Thus, identification of determinants differentiating high risk STEC (HUS STEC) from
low risk STEC (non-HUS STEC) is needed to enable implementation of graded infectious disease response.
Methods: A national study of 333 STEC infections in Norway, including one STEC from each patient or outbreak
over two decades (1992–2012), was conducted. Serotype, virulence profile, and genotype of each STEC were
determined by phenotypic or PCR based methods. The association between microbiological properties and
demographic and clinical data was assessed by univariable analyses and multiple logistic regression models.
Results: From 1992 through 2012, an increased number of STEC cases including more domestically acquired
infections were notified in Norway. O157 was the most frequent serogroup (33.6 %), although a decrease of this
serogroup was seen over the last decade. All 25 HUS patients yielded STEC with stx2, eae, and ehxA. In a multiple
logistic regression model, age ≤5 years (OR = 16.7) and stx2a (OR = 30.1) were independently related to increased
risk of HUS. eae and hospitalization could not be modelled since all HUS patients showed these traits. The
combination of low age (≤5 years) and the presence of stx2a, and eae gave a positive predictive value (PPV) for
HUS of 67.5 % and a negative predictive value (NPV) of 99.0 %. SF O157:[H7] and O145:H?, although associated with
HUS in the univariable analyses, were not independent risk factors. stx1 (OR = 0.1) was the sole factor independently
associated with a reduced risk of HUS (NPV: 79.7 %); stx2c was not so.
Conclusions: Our results indicate that virulence gene profile and patients’ age are the major determinants of
HUS development.
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Background
Shiga toxin-producing Escherichia coli (STEC), also
called verocytotoxin-producing E. coli (VTEC), can lead
to mild, self-limiting diarrhoea, haemorrhagic colitis or
the life threatening complication haemolytic uremic
syndrome (HUS). Children less than five years of age,
the elderly, and immunocompromised persons, are
most susceptible to STEC infection as well as to severe
complications [1]. An association between the Shiga
Toxin-encoding gene stx2, particularly the subtypes
stx2a, stx2c, and stx2d, and development of HUS has
been described [2–10]. Several other virulence factors
that contribute to the pathogenicity of STEC have been
identified, such as eae (E. coli attaching and effacing)
encoding intimin and the plasmid-borne ehxA encoding
enterohaemolysin [11]. In several parts of the world
O157 is the predominating STEC serogroup, and this
variant has most frequently been associated with HUS
and outbreaks [12–16]. In other countries, however,
like continental Europe and Scandinavia, non-O157
serogroups are dominating [3, 17–20]. The involvement
of STEC in serious outbreaks combined with a high dis-
ease burden per case [21] makes STEC a significant
challenge to public health.
In 1995, STEC infection was made mandatory no-
tifiable to the Norwegian Surveillance System for
Communicable Diseases (MSIS) (http://www.msis.no),
and in 2006 diarrhoea-associated HUS became notifi-
able. Norway has implemented strict guidelines for pre-
vention and control of STEC infection, in which 3–5
negative stool cultures are required for high-risk
groups [22].
A few previous studies have investigated risk factors
for development of HUS, however these studies have
mainly focused on clinical and demographic parameters
among patients infected with either serogroup O157 or
O104 [23–25]. Although it is well documented that the
presence of stx2 and eae as well as being a child are
risk determinants of HUS development, few studies
have performed multivariable analyses of both O157
and non-O157 STEC to identify factors independently
associated with HUS. Furthermore, knowledge of fac-
tors independently associated with reduced risk of HUS
is sparse.
The main aim of the present study was to identify
microbiologic and patient-related criteria differen-
tiating HUS STEC from non-HUS STEC, in order to
obtain information enabling revision of the strict con-
trol and prevention measures presently employed in
Norway. The second aim was to describe human STEC
infections in Norway during two decades (1992–2012),
to compare with studies from other countries and
contribute to our understanding of this infection
in general.
Methods
Surveillance of STEC infections in Norway
Epidemiological and clinical information about STEC in-
fection in Norway from 1992 through 2012 was obtained
from MSIS at the National Institute of Public Health
(NIPH), which has received mandatory notifications
from medical microbiological laboratories and physicians
in the country since 1995 (http://www.msis.no/). During
this period, 513 STEC infections were notified (Fig. 1)
(annual mean, 0.54 cases per 100.000 populations).
Cases were recorded as domestic if the patients did not
report foreign travel in the incubation period, and as
imported if the patients became ill while being abroad or
shortly after their return home.
Characterization of STEC isolates
All isolates were obtained from the National STEC
Culture Collection at the Reference Laboratory for
Enteropathogenic Bacteria at the NIPH, which receives
all presumptive STEC isolates from medical microbio-
logical laboratories throughout Norway.
We selected one isolate per patient and per outbreak,
except for one patient from whom two isolates were
included since they showed different virulence gene pro-
files and genotypes. Likewise, only one isolate was se-
lected if isolates with identical genotype were received
within the same time period from two patients with dif-
ferent surnames, but living within the same municipality
or county, had attended the same child-care facility, or
had identical travel history. Nine isolates were from
asymptomatic carriers. In total, 334 STEC isolates from
333 patients (64.8 %, 333/513) were included in the
study (Fig. 1).
Eighty-three out of the 334 STEC isolates, all from pa-
tients living in one of the 19 counties in Norway, have
been described previously [26].
Serotyping
Presumptive STEC isolates submitted to the Reference
Laboratory at NIPH were serotyped by slide agglutination
using antisera against 43 different O groups (Institut für
Immunpräparate und Nährmedien GmbH Berlin (SIFIN),
Germany, and Statens Serum Institute (SSI), Denmark)
and eight H groups (SSI, Denmark). Non-agglutinating
isolates were re-tested by molecular serotyping, in which
PCR was run to amplify the wzx or wzy genes of 14 O
groups (O26, O86, O91, O103, O104, O111, O113, O114,
O117, O121, O128, O145, O146, and O157) and the fliC
gene of 10 H groups (H2, H4, H7, H8, H10, H11, H19,
H21, H25, and H28) (Lindstedt et al., unpublished).
Sorbitol-fermenting (SF) E. coli O157
All STEC isolates belonging to serogroup O157 were
analysed with a multiplex PCR (M-PCR) specific for SF
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E. coli O157 [27] in order to distinguish SF O157 STEC
from the classical non-sorbitol fermenting (NSF) O157
STEC.
Virulence genes characterization
From 1992 to 2001, production of Stx1 and Stx2 was
ascertained using the GM1 ganglioside enzyme-linked
immunosorbent assay (GM1-ELISA) with some minor
modifications [28]. In 2001 the ELISA was replaced by a
M-PCR detecting stx1 and stx2 [29]. The same year a
PCR detecting eae was also included [30, 31]. Since
July 2005 an octaplex-PCR [32], later expanded to an
endecaplex-PCR, was used for routine screening of all
enteropathogenic E. coli. This encompassed primers for
stx1, stx2, eae, ehxA, bfpB and rrs [33], as well as
primers for ipaH [34], LTI (F-primer; GTT TTA TTT
ACG GCG TTA CTA TCC and R-primer; ATT GGG
GGT TTT ATT ATT CC), STIa [35], STIb [35], and
aggR [34]. All STEC isolates confirmed before July 2005
were re-tested for eae and ehxA using the PCR primers
described by Brandal et al. [33].
stx subtyping
Subtypes of stx1 were identified by PCR as described by
Scheutz et al. [8]. Subtyping of stx2 was performed with
one of the two following methods. The first method used
PCR restriction fragment length polymorphism (RFLP)
followed by electrophoresis (modification of Russmann et
al. [36] and Jelacic et al. [37]), and sequencing [7], in
which all stx2d positive isolates were verified by a stx2d
specific PCR [38]. The second method determined stx2
subtypes by PCR as described by Scheutz et al. [8].
Genotyping
The O157 isolates were genotyped by an O157 specific
multi-locus variable-number tandem repeat analysis
(MLVA) [39]. All non-O157 STEC isolates were geno-
typed using a seven loci generic MLVA [40] or an up-
dated 10 loci generic MLVA [41].
Statistical methods
Statistical analyses were performed using the computer
program SPSS® release 20.0.0 (IBM SPSS Software,
International Business Machines Corp., Armonk New
York). Univariable analyses were performed with the pro-
cedures for cross tables (dichotomous variables) or com-
parison of means (continuous variables) as appropriate.
Binary logistic regression was implemented for multivari-
able analyses. The results are reported as odds ratios with
95 % confidence intervals and two-tailed p values. A
p value of ≤ 0.05 was considered statistically significant.
Positive and negative predictive values were calculated as
described by Altman & Bland [42].
Ethical considerations
At the NIPH, all STEC strains are routinely collected for
disease surveillance and outbreak detection. The current
study is based on descriptive analysis of bacterial isolates
from the strain collection and the microbiological char-
acteristics so obtained could only be combined with the
Fig 1 STEC in Norway 1992 to 2012. All STEC infections notified to MSIS during this time period were shown (grey columns, n = 513). Only one
STEC isolate per outbreak and per patient was included in the present study (black columns, n = 334 STEC isolates from 333 patients). Before 2006
the main focus of the clinical microbiological laboratories throughout Norway was detection of STEC O157. However, from 2007 the majority of
these laboratories implemented techniques for detection of stx/Stx and the number of non-O157 cases increased. In 2006, 2009, and 2012, larger
STEC outbreaks (>5 cases) were reported (Additional file 1)
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sex, age, clinical outcome, hospitalization, travel history,
and seasonality for the patients from which the strains were
isolated. Ethical approval was therefore not required. Also,
the Norwegian Communicable Disease Control Act and its
companying regulations (https://lovdata.no/dokument/NL/
lov/1994-08-05-55?q=Smittevernloven) obliges the NIPH
to perform national surveillance of communicable dis-
eases, including STEC infection. For these reasons, con-
sent was not obtained from the patients to analyze the
bacterial samples for this research project.
Results
STEC infections in Norway
From 1992 to 2006, 0–20 STEC cases were notified each
year, whereas from 2006 the number of notified cases in-
creased, ranging from 22 to 111 annually (mean 54.9)
(Fig. 1). Of the 513 patients recorded by surveillance, 57
developed HUS (11.1 %), and isolates from 36 of them
were submitted to the National Reference Laboratory at
NIPH. The major outbreaks reported in Norway during
1992 through 2012 are presented in Additional file 1.
Demographics and clinical presentation
The mean age of the 333 patients selected for the study
was 24.6 years and 39.0 % (130/333) were ≤ 5 years old.
Diarrhoea was the most frequent clinical manifestation,
and 35.7 % (119/333) reported bloody diarrhoea (Table 1).
Twenty-five of the patients (7.5 %) developed HUS
(Additional file 2). Furthermore, 49.8 % had reportedly ac-
quired their infection in Norway (Table 1), but a higher
proportion of domestically acquired STEC infections was
observed from 2006 compared to previous years (127/190,
66.8 % (from 2006) versus 39/83, 46.7 % (before 2006),
p < 0.005).
Table 1 Association between patient-related factors in O157 versus non-O157 and HUS versus non-HUS STEC infections, Norway
1992–2012
Characteristics No. (%) of patients
All (333) O157
(112, 33.6 %)
Non-O157
(221, 66.4 %)
p-valuea HUS
(25, 7.5 %)
Non-HUS
(308, 92.5 %)
p-value
Sex Male 146 (43.8 %) 47 99 9 137
Female 187 (56.2 %) 65 122 16 171
Age group (yr) ≤5 130 (39.0 %) 25 105 <0.005 22 108 <0.005
6-18 41 (12.3 %) 16 25 2 39
19-41 76 (22.8 %) 30 46 0 76
42-64 51 (15.4 %) 23 28 0 51
≥65 35 (10.5 %) 18 17 1 34
Age mean 24.6 33.9 20.33 <0.005 4.72 26.2 <0.005
HUS Yes 25 (7.5 %) 9 16 25 0
No 308 (92.5 %) 103 205 0 308
Clinical outcome Bloody diarrhea 119 (35.7 %) 40 79 13 106 <0.005
Diarrhea 148 (44.4 %) 57 91 1 147 <0.005
Asymptomatic 9 (2.7 %) 0 9 0 9
Unknown 57 (17.1 %) 15 42 11 46
Hospitalized Yes 141 (42.2 %) 64 77 24 117
No 155 (46.4 %) 39 116 <0.005 0 155 <0.005
Unknown 37 (11.1 %) 9 28 1 36
Travel history Domestically 166 (49.8 %) 40 126 16 150
Imported 107 (32.1 %) 57 50 <0.005 3 104
Unknown 60 (18.0 %) 15 45 6 54
Seasonalityb Summer 118 (35.4 %) 50 68 6 112
Autumn 74 (22.2 %) 20 54 9 65
Winter 75 (22.5 %) 24 51 7 68
Spring 66 (19.8 %) 18 48 3 63
aOnly p-values ≤ 0.05 were shown
bSummer; June-August, Autumn; September-November, Winter; December-February, Spring; March-May
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Characterization of selected STEC
Serogroups
Twenty-four different O groups were identified among
292 of the 334 STEC isolates examined from 333 pa-
tients. The remaining 42 isolates were non-typable with
the methods employed (one of these was rough). The
majority of the isolates (69.5 %, 232/334) were motile,
and nine H groups were discerned. Thus, a total of 58
different O and H combinations were identified.
O157 was the most frequent serogroup detected (112/
333, 33.6 %) (Table 1). The percentage of serogroup
O157 significantly decreased from 49.6 % (65/131) during
1992–2006, to 23.3 % (47/202) in 2007–2012 (p < 0.005).
Compared to non-O157, O157 infection was significantly
associated with older age, foreign travel prior to disease
onset, and a higher rate of hospitalization. No statistical
significant differences between O157 and non-O157 in-
fected persons were detected regarding clinical outcome
(Table 1).
Serogroup O157 included 103 isolates that were NSF
and nine that were SF. NSF O157 infections were more
likely to occur during summer and spring, whereas in-
fections with SF O157 were associated with colder
months of the year. None of the patients with SF O157
infection reported foreign travel prior to onset of disease
(Additional file 3). In a multivariable model, both foreign
travel and seasonality (summer) were independently
related to NSF O157 infection (OR = 4.4, CI = 2.5-7.5
and OR = 1.9, CI = 1.1-3.3, respectively).
Non-O157 STEC infection was detected in 66.4 % of
the patients (221/333) (Table 1). The most common ser-
ogroups were O103 (15.0 %), O26 (10.2 %), O145
(7.2 %), O91 (3.9 %), O117 (3.3 %), O121 (2.1 %), O113
(1.8 %), O146 (1.8 %), and O111 (1.2 %). Infection with
STEC O103, O26, or O121 was associated with younger
age. Additionally, patients infected with O103 or O145
were less likely to report foreign travel prior to infection
(Additional file 3).
Virulence genes
Of the 334 STEC from 333 patients, 127 (38.1 %) carried
stx1 only, 118 (35.3 %) harboured stx2 only, and 89
(26.6 %) exhibited both stx1 and stx2. Thus, isolates
from 215 patients (64.6 %) were positive for stx1 and
207 (62.2 %) carried stx2 (Table 2). None of the stx1
positive isolates harboured more than one stx1 subtype.
stx1a was the most frequently detected subtype. Of the
patients with stx2 positive STEC, 100 (48.3 %) contained
stx2c and 85 (41.1 %) carried stx2a . Nearly three-
fourths of the patients had an eae positive STEC and the
majority of the cases harboured STEC with ehxA
(Table 2).
Patients with O157 and non-O157 STEC did not differ
with regard to presence of stx1 (Table 2). However, when
Table 2 Association between virulence genes, serogroups, HUS, and hospitalization among 333 cases of STEC infection, Norway
1992–2012
Virulence genes No. (%) of patients
All (333) O157
(112, 33.6 %)
Non-O157
(221, 66.4 %)
p-valuea HUS
(25, 7.5 %)
Non-HUS
(308, 92.5 %)
p-value Hospitalizedb
(141, 42.3 %)
p-value
stx1 215 (64.7 %) 66 150 1c 214 <0.005 83 0.01
stx1a 189 66 123 1 188 <0.005 75
stx1c 23 0 23 <0.005 0 23 7
stx1d 3 0 3 0 3 1
stx2 207d (62.2 %) 109 98 <0.005 25e 182 <0.005 106 <0.005
stx2a 85 32 53 24 61 <0.005 51 <0.005
stx2b 32 0 32 <0.005 0 32 6 0.05
stx2c 100 92 8 <0.005 2 98 0.01 57 <0.005
stx2d 9 1 8 0 9 4
stx2g 2 0 2 0 2 NDf
eae 246 (73.9 %) 112 134 <0.005 25 220 <0.005 117 0.02
ehxA 283 (85.0 %) 109 174 <0.005 25 258 131 <0.005
aOnly p-values ≤ 0.05 were shown
bNo information on hospitalization was available for 37 patients. These patients carried STEC with the following stx genes; stx1a (n = 17), stx1c (n = 1), stx1d (n = 2),
stx2a (n = 6), stx2b (n = 9), stx2c (n = 10), and stx2g (n = 2) (n = number of patients) (some patients carried STEC with more than one stx subtype)
cFrom one HUS patient two different non-O157 STEC isolates were included. One with stx1a and another with stx1a + stx2a and this patient was included both in
the stx1 and stx1a groups as well as in the stx2 and stx2a groups
dIncluding 21 patients with STEC harbouring more than one stx2 subtype; stx2a + stx2c (n = 19), stx2a + stx2d (n = 1), and stx2c + stx2d (n = 1)
eOne HUS patient carried a STEC with both stx2a + stx2c and this patient was included within the stx2a group as well as in the stx2c group
fND: not determined
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stx1 was stratified according to subtypes, stx1c was more
frequently detected among patients with non-O157
STEC, and neither stx1c nor stx1d was found in any
of the patients with O157 isolates (Table 2, Additional
file 4).
Nearly all patients with O157 isolates carried stx2, while
less than half of their non-O157 counterparts had this
gene. Among the stx2 subtypes, stx2c and stx2a + stx2c
were both more common in O157 (p < 0.005 for each),
whereas stx2b and stx2g were only detected in the non-
O157 group (Table 2, Additional file 4).
Both eae and ehxA were more frequently detected in
O157 compared to non-O157 (Table 2).
Within O157, NSF O157 were associated with stx2,
eae and ehxA, whereas SF O157 were less likely to
harbour stx1 (Additional file 3).
Among non-O157 isolates, O103 was more likely to
carry stx1 than the other serogroups combined, while
in O145 or O121 stx1 was infrequent. All O91, O113,
and O146 isolates were eae negative, and only two of
the O117 isolates carried this gene (Additional file 3).
Patients with stx1 positive STEC showed a reduced
risk of hospitalization, whereas the contrary was seen
for patients with stx2, eae, and ehxA (Table 2).
Discrimination between HUS and non-HUS STEC
All 25 HUS patients, except three, were ≤ 5 years. Com-
pared to non-HUS cases, patients with HUS were more
often hospitalized and showed bloody stools (Table 1).
Seven serogroups were found among STEC from HUS
patients: O157 (including both NSF O157 and SF O157
isolates), O145, O26, O103, O121, O111, and O86
(Additional file 2), however only serogroups SF O157 and
O145 were significantly associated with HUS (Table 3 and
Additional file 3). Within serogroup O145, four of the
six patients with STEC O145:H? presented with HUS
(p < 0.005, PPV:66.7 %, NPV:93.6 %), whereas only one of
eighteen patients with O145:H28 showed this complica-
tion. No significant association between HUS and ser-
ogroup O103 was seen, but all three patients with STEC
O103:H25 developed HUS.
All HUS patients carried STEC with stx2, eae, and
ehxA, however only stx2 and eae were significantly asso-
ciated with HUS, while ehxA was not (Table 2 and 3).
stx2a was present in 24/25 HUS STEC (including one
with stx2a + stx2c), whereas the last case carried stx2c
only. Both stx1 and stx2c were negatively associated with
HUS (Table 2 and 3). The combination of age ≤ 5 years
and STEC possessing stx2a and eae showed strong
Table 3 Risk factors for HUS among 333 STEC patients, Norway, 1992–2012
Determinanta No. of patients Predictive valuesb Univariable analysesc Multivariable analysesc, d
All (333) HUS (25) PPV NPV OR (95 % CI) Model 1
(risk factors)
Model 2
(preventive factors)
Model 3
(all factors)
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Age≤ 5 yr 130 22 16.9 % 98.5 % 13.6 (4.0-46.4) 12.2 (3.2-46.7) 16.7 (4.24-65.7)
Bloody diarrhea 119 13 10.9 % 99.4 % 19.5 (2.5-151.3 NDe
Diarrhea 148 1 0.7 % 78.1 % 0.1 (0.008-0.5) ND
Hospitalizedf 141 24 17.0 % 100.0 % ND
SF O157 9 5 55.6 % 93.8 % 19.0 (4.7-76.3) NSg
O145 24 5 20.8 % 93.5 % 3.8 (1.3-11.2)
O145:H? 6 4 66.7 % 93.6 % 29.1 (5.0-168.4) NS
stx1 215 1h 0.5 % 79.7 % 0.02 (0.002-0.1) 0.02 (0.002-0.1) 0.1 (0.01-0.8)
stx1a 189 1h 0.5 % 83.3 % 0.03 (0.004-0.2)
stx2 207 25 12.1 % 100.0 % ND
stx2a 85 24 28.2 % 99.6 % 97.2 (12.9-732.5) 92.7 (10.7-803.5) 30.1 (3.3-271.9)
stx2c 100 2 2.0 % 90.1 % 0.2 (0.04-0.8 0.2 (0.03-0.7) 0.6 (0.1-3.3)
eae 245 25 10.2 % 100.0 % ND
aAll determinants associated with HUS (p ≤ 0.05) were included
bPPV; positive predictive value, NPV; negative predictive value
cOR; odds ratio, CI; 95 % confidence interval
dModel 1; factors related to increased risk of developing HUS, Model 2; factors related to reduced risk of HUS, and Model 3; comprising both factors related to
increased and decreased risk of HUS
eND; not determined since all HUS cases were hospitalized and all HUS isolates carried stx2 and eae
fInformation on hospitalization was not available for 37 patients, including one HUS patient
gNS; not statistically significant
hOne HUS patients had two STEC isolates; one with stx1a + stx2a and another with stx1a only
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association to HUS development with PPV of 64.7 %
and NPV of 99.0 %. Additionally, this combination gave
the highest sensitivity (88.0 %) and specificity (96.1 %) of
all determinants investigated (data not shown).
Three multivariable models were fitted, with and without
including potentially protective factors. In the first model,
two factors were found to be independently related to
increased risk of developing HUS: stx2a (OR = 92.7,
CI = 10.7-803.5) and age ≤ 5 years (OR= 12.2, CI = 3.2-46.7).
In this model, the following factors were not independ-
ently associated with HUS: SF O157 and O145:H?, al-
though they were significant in the univariable analysis
(Table 3). No first-order interactions were detected in the
model. All HUS patients with bloody diarrhoea carried
STEC with stx2a, and bloody diarrhoea was therefore not
included in the model containing stx2a. Furthermore, eae,
stx2, and hospitalization could not be modelled since all
HUS patients showed this trait (for one HUS patient no
information on hospitalization was available).
In a separate model assessing protective factors only,
both stx1 (OR = 0.02, CI = 0.002-0.1) and stx2c (OR = 0.2,
CI = 0.03-0.7) were independently associated with reduced
risk of HUS (Table 3). Non-bloody diarrhoea was not
included in the model as only one HUS patient showed
this symptom. In the third model comprising stx2a, age,
stx1 and stx2c, stx1 was still related to reduced risk of
HUS development (OR = 0.1, CI = 0.01-0.8), whereas stx2c
was not (OR = 0.6, CI = 0.1-3.3) (Table 3).
Discussion
Low age (≤5 years), and the presence of STEC with stx2a
and eae were identified as risk factors for HUS develop-
ment. An association between HUS and these parame-
ters has been seen in several studies [2–10, 16–18, 43],
however, only a few have explored this by multivariable
analysis [2, 7, 44]. The high NPV (99.0 %) obtained for
this combination of determinants indicates that the like-
lihood of developing HUS is very low when all these fac-
tors are negative. However, not all patients with these
three risk factors developed HUS (PPV of 64.7 %), em-
phasizing that other strain characteristics or host specific
factors, like the patient’s immunocompetence, also are
important to consider when assessing a patients’ risk for
developing HUS. Bloody diarrhoea has previously been
identified as a risk factor for HUS [2], and a similar asso-
ciation was achieved in our study, although not proven
as an independent risk factor. Interestingly, when only
including protective factors in a multivariable model,
stx2c was independently associated with reduced risk of
HUS, but not when both protective and risk factors were
included in the same model. The role of stx2c in HUS
pathogenesis has been debated and it has been specu-
lated that stx2c merely assists stx2a during development
of this severe complication [7]. However, our results
indicated that stx2c neither was sufficient nor necessary
for HUS development. In one of the two HUS patients
with stx2c positive STEC, stx2c and stx2a were both
present, whereas in the second case stx2c was the sole
stx gene detected. It is possible, though, that this isolate
had lost the stx2a encoding bacteriophage, a phe-
nomenon previously described in isolates from HUS
patients [45, 46]. stx1 was independently related to re-
duced risk of HUS in two multivariable models. This has
to our knowledge never been shown before, although such
an association has been suggested [3, 16, 26, 47–50]. None
of the HUS patients carried STEC with stx1 as the sole stx
gene present. The single HUS patient with stx1 yielded
two O111:[H8] isolates, one with stx1a + stx2a and the
other with stx1a only, indicating that stx2a was the stx
gene responsible for HUS development. Recently, it was
demonstrated that STEC O111:H8 strains frequently lose
their stx2 encoding bacteriophage during in vitro growth,
suggesting that this loss may occur in vivo as well [3, 51].
Moreover, stx1 showed a low PPV for HUS, a finding
which further emphasises that stx1 was not a key factor
for HUS development.
In contrast to some authors [3, 15, 16, 52], but in con-
cordance with others [2, 7], we did not find any signifi-
cant difference between STEC O157 and non-O157
regarding HUS. Interestingly, of the O157 STEC isolated
from HUS patients, SF O157 was the dominating vari-
ant, despite the fact that NSF O157 was the most fre-
quent STEC detected in Norway. A high frequency of SF
O157 in HUS cases has also been reported from other
European countries [9, 53] and it has been suggested
that patients with STEC SF O157 more often develop
HUS compared to patients with NSF O157 [54, 55]. Fur-
thermore, SF O157 and O145 (particularly O145:H?)
were the only serogroups associated with HUS in our
univariable analyses, although they were not significant
in the multivariable models. All STEC O145:H? and SF
O157 cases were domestically acquired, indicating a res-
ervoir of these bacteria in Norway. Both serogroups have
previously been responsible for HUS outbreaks in our
country [56].
Our results confirm that the severity of STEC illness
depends strongly on the virulence gene profile of the
infecting STEC as well as the patients’ age, unlike ser-
ogroup affiliation [2, 57, 58]. Nevertheless, exceptions
exist and therefore clinical findings and the epidemio-
logical situation of each STEC case have to be con-
sidered before proper control and prevention measures
can be implemented.
In Norway infections with non-O157 STEC were more
common than infections with O157 isolates, in ac-
cordance with findings from several other countries
[3, 17–19, 59–61]. Expectedly, the proportion of STEC
O157 declined compared to non-O157 from approximately
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2007, when improved methods for detecting stx/Stx were
implemented in the majority of clinical microbiological
laboratories in Norway [3, 16, 50, 61, 62]. In contrast to
reports from other countries, more than half of the STEC
O157 infections in Norway were imported and no sea-
sonal differences between O157 and non-O157 infections
were seen [16, 63, 64]. Since ruminants are the main reser-
voir of STEC O157 [65], the low prevalence of STEC
O157 among ruminants in Norway might explain these
findings [66–69]. Non-O157 infections were more fre-
quently seen in children (≤5 years) and were more often
domestically acquired than O157 infections. Contact with
ruminants has previously been identified as the strongest
risk factor for non-O157 infection in young children [70]
and the following data indicate that this might be the case
also in Norway: A national survey of Norwegian sheep
flocks [69] showed that as many as 17.3 % (85/491) of the
flocks carried non-O157 E. coli considered to be human
pathogens (unpublished data). Also, non-O157 STEC out-
breaks associated with sheep contact or eating mutton
have been reported in Norway [71, 72].
There are some limitations to our study. Firstly, we did
not examine a consecutive series of STEC isolates from the
National STEC Culture Collection, but selected one STEC
per patient and per outbreak. Therefore a correct incidence
of STEC isolates was not achieved. However, the main aim
of our study was to define factors discriminating HUS-
STEC from non-HUS STEC. Inclusion of all STEC isolates
would have given a biased contribution of the different
parameters due to overrepresentation of isolates involved
in outbreaks. Secondly, it is likely that non-O157 STEC
were underestimated before 2007 since the sensitivity of
diagnostic methods were suboptimal at that time. Al-
though the laboratory methods have improved, non-O157
STEC isolation is still a diagnostic challenge due to lack of
a selective growth media with sufficient sensitivity. Thirdly,
the number of HUS cases included in the study was too
low to identify other than the strongest risk factors. Finally,
the available clinical information did not permit detailed
analysis of patient-related factors such as underlying ill-
nesses, antibiotic treatment, and co-infections, all of which
have been considered as putative risk factors for HUS.
Conclusions
Our results showed that the characteristics of the Norwe-
gian STEC isolates were in concordance with data from
other countries. However, some country specific charac-
teristics were unravelled. Multivariable regression analyses
identified low age (≤5 years) and the presence of stx2a as
independent risk factors for HUS development. Addition-
ally, all HUS STEC carried eae. On the other hand, stx1
was independently associated with reduced risk of HUS.
Hence, the virulence profile and the patients’ age - but not
particular serogroups - were the essential determinants
discriminating HUS STEC from non-HUS STEC. The
results achieved from the current study will contribute, to-
gether with previous published knowledge, to revision of
the strict national guidelines for prevention and control of
STEC infections currently applied in Norway. Nevertheless,
it should be emphasized that in addition to the risk factors
identified, the clinical presentation of each patient and the
epidemiological context also should be taken into account
before advice of control and prevention can be given.
Additional files
Additional file 1: Reported outbreaks of human STEC infections,
Norway 1992–2012. Characteristics of both local and nationwide STEC
outbreaks detected in Norway from 1992–2012.
Additional file 2: STEC isolates from HUS patients included in the
present study, Norway 1992–2012. Microbiological characteristics of
STEC isolates (n = 26) from haemolytic uremic syndrome (HUS) patients
and characteristics of patients with HUS (n = 25) in Norway from 1992–2012.
Additional file 3: Characteristics associated with the most common
STEC serogroups, Norway 1992–2012. Demographic, clinical, and
virulence characteristics among STEC harbouring the most common
serogroups, Norway from 1992–2012.
Additional file 4 Distribution of stx genotypes in STEC O157
compared to non-O157 STEC, Norway 1992–2012. Distribution and
combination of stx1 and stx2 subtypes in STEC O157 compared to
non-O157 STEC, Norway from 1992–2012.
Abbreviations
CI: Confidence interval; eae: E. coli attaching and effacing; ehxA: Enterohaemolysin;
HUS: Haemolytic uremic syndrome; NIPH: Norwegian Institute of Public Health;
NPV: Negative predictive value; NSF: Non-sorbitol fermenting; MLVA: Multiple-
locus variable-number of tandem repeat analysis; MSIS: The National
Surveillance System for Communicable Diseases; OR: Odds ratio; PPV: Positive
predictive value; SF: Sorbitol-fermenting; STEC: Shiga toxin-producing E. coli;
Stx: Shiga toxin; VTEC: Verocytotoxigenic E. coli.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LTB led the design of the study and writing of the manuscript. All authors
contributed to the writing and reviewing of the paper. LTB, ALW, LV, and GK
were involved in the project design. LTB, ALW, IL, and BAL participated in
the design, analyses, and interpretation of the microbiological data. HL and
LV were responsible for the patient-related data. GK performed the statistical
analyses. LTB, ALW, HL, and GK interpreted the statistical data. All authors
read and approved the final manuscript.
Acknowledgements
We want to thank the staff at the Department of Foodborne Infections at
the Norwegian Institute of Public Health for skillful technical assistance,
including Torbjørn Bruvik who was involved in molecular serotyping and stx
subtyping. We also would like to thank Kirsten Konsmo at the Department of
Infectious Disease Epidemiology at the Norwegian Institute of Public Health
for quality assurance of the MSIS data. Finally, we will thank all medical
microbiological laboratories in Norway for the tremendous work load put
into isolating STEC from patient samples and forwarding the isolates to the
NIPH for further characterization. Infection control of STEC on both the local
and national level relies heavily on their efforts.
Author details
1Department of Foodborne Infections, The Norwegian Institute of Public
Health, Oslo, Norway. 2Department of Infectious Disease Epidemiology, The
Norwegian Institute of Public Health, Oslo, Norway. 3Gene Technology
Section, Akershus University Hospital, Lørenskog, Norway. 4Division of
Brandal et al. BMC Infectious Diseases  (2015) 15:324 Page 8 of 10
Infectious Disease Control, The Norwegian Institute of Public Health, Oslo,
Norway. 5Department of Food Safety and Infection Biology, Norwegian
University of Life Sciences, Oslo, Norway. 6Division of Infectious Disease
Control, Department of Foodborne Infections, Norwegian Institute of Public
Health, P.O. Box 4404, Nydalen N-0403Oslo, Norway.
Received: 5 December 2014 Accepted: 8 July 2015
References
1. Webster K, Schnitzler E. Hemolytic uremic syndrome. Handb Clin Neurol.
2014;120:1113–23.
2. Ethelberg S, Olsen KE, Scheutz F, Jensen C, Schiellerup P, Enberg J, et al.
Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect
Dis. 2004;10:842–7.
3. Buvens G, De Gheldre Y, Dediste A, de Moreau AI, Mascart G, Simon A, et al.
Incidence and virulence determinants of verocytotoxin-producing Escherichia
coli infections in the Brussels-Capital Region, Belgium, in 2008–2010. J Clin
Microbiol. 2012;50:1336–45.
4. Mellmann A, Bielaszewska M, Kock R, Friedrich AW, Fruth A, Middendorf B,
et al. Analysis of collection of hemolytic uremic syndrome-associated
enterohemorrhagic Escherichia coli. Emerg Infect Dis. 2008;14:1287–90.
5. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, et al.
Escherichia coli harboring Shiga toxin 2 gene variants: frequency and
association with clinical symptoms. J Infect Dis. 2002;185:74–84.
6. Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. Shiga
toxin activatable by intestinal mucus in Escherichia coli isolated from
humans: predictor for a severe clinical outcome. Clin Infect Dis.
2006;43:1160–7.
7. Persson S, Olsen KE, Ethelberg S, Scheutz F. Subtyping method for
Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to
clinical manifestations. J Clin Microbiol. 2007;45:2020–4.
8. Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, Karch H, et al. Multicenter
evaluation of a sequence-based protocol for subtyping Shiga toxins and
standardizing Stx nomenclature. J Clin Microbiol. 2012;50:2951–63.
9. Marejkova M, Blahova K, Janda J, Fruth A, Petras P. Enterohemorrhagic
Escherichia coli as causes of hemolytic uremic syndrome in the Czech
Republic. PLoS One. 2013;8:e73927.
10. European Center for Disease Prevention and Control: Surveillance of
food- and waterborne diseases in the EU/EEA - 2006–2009. ECDC 2013,
[http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_
DispForm.aspx?List = 4f55ad51-4aed-4d32-b960-af70113dbb90&ID = 900]
11. Melton-Celsa A, Mohawk K, Teel L, O'Brien A. Pathogenesis of Shiga-toxin
producing escherichia coli. Curr Top Microbiol Immunol. 2012;357:67–103.
12. Vally H, Hall G, Dyda A, Raupach J, Knope K, Combs B, et al. Epidemiology
of Shiga toxin producing Escherichia coli in Australia, 2000–2010. BMC
Public Health. 2012;12:63.
13. Rivero MA, Passucci JA, Rodriguez EM, Parma AE. Seasonal variation of HUS
occurrence and VTEC infection in children with acute diarrhoea from
Argentina. Eur J Clin Microbiol Infect Dis. 2012;31:1131–5.
14. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al.
Foodborne illness acquired in the United States–major pathogens.
Emerg Infect Dis. 2011;17:7–15.
15. Locking ME, Pollock KG, Allison LJ, Rae L, Hanson MF, Cowden JM.
Escherichia coli O157 infection and secondary spread, Scotland, 1999–2008.
Emerg Infect Dis. 2011;17:524–7.
16. Gould LH, Mody RK, Ong KL, Clogher P, Cronquist AB, Garman KN, et al.
Increased recognition of non-O157 Shiga toxin-producing Escherichia coli
infections in the United States during 2000–2010: epidemiologic features and
comparison with E. coli O157 infections. Foodborne Pathog Dis. 2013;10:453–60.
17. Beutin L, Krause G, Zimmermann S, Kaulfuss S, Gleier K. Characterization of
Shiga toxin-producing Escherichia coli strains isolated from human patients
in Germany over a 3-year period. J Clin Microbiol. 2004;42:1099–108.
18. Kappeli U, Hachler H, Giezendanner N, Beutin L, Stephan R. Human
infections with non-O157 Shiga toxin-producing Escherichia coli,
Switzerland, 2000–2009. Emerg Infect Dis. 2011;17:180–5.
19. van Duynhoven YT, Friesema IH, Schuurman T, Roovers A, van Zwet AA,
Sabbe LJ, et al. Prevalence, characterisation and clinical profiles of Shiga
toxin-producing Escherichia coli in The Netherlands. Clin Microbiol Infect.
2008;14:437–45.
20. European Food Safety Authority ECfDPaC: The European Union Summary
Report on Trends and Sources of Zoonoses, Zoonotic Agents and
Food-borne Outbreaks in 2011. EFSA Journal 2013,11:3129 [250 pp.].
doi:10.2903/j.efsa.2013.3129 2013.
21. Blaser MJ. Deconstructing a lethal foodborne epidemic. N Engl J Med.
2011;365:1835–6.
22. Norwegian Institute of Public Health: E. coli-enteritt (inkludert EHEC-infeksjon
og HUS). Smittevernboka 2013 [In Norwegian], [http://www.fhi.no/eway/
default.aspx?pid = 239&trg = Content_6493&Main_6157 = 6287:0:25,5499&Main
Content_6287 = 6493:0:25,6833&Content_6493 = 6441:82709::0:6446:32:::0:0]
23. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, et al.
Risk factors for the hemolytic uremic syndrome in children infected with
Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis.
2012;55:33–41.
24. Werber D, King LA, Muller L, Follin P, Buchholz U, Bernard H, et al.
Associations of age and sex with the clinical outcome and incubation
period of Shiga toxin-producing Escherichia coli O104:H4 infections, 2011.
Am J Epidemiol. 2013;178:984–92.
25. Zoufaly A, Cramer JP, Vettorazzi E, Sayk F, Bremer JP, Koop I, et al. Risk
factors for development of hemolytic uremic syndrome in a cohort of adult
patients with STEC 0104:H4 infection. PLoS One. 2013;8:e59209.
26. Haugum K, Brandal LT, Lindstedt BA, Wester AL, Bergh K, Afset JE. PCR-
Based Detection and Molecular Characterization of Shiga Toxin-Producing
Escherichia coli Strains in a Routine Microbiology Laboratory over 16 years.
J Clin Microbiol. 2014;52:3156–63.
27. Haugum K, Lindstedt BA, Lobersli I, Kapperud G, Brandal LT. Identification of
the anti-terminator qO111:H)- gene in Norwegian sorbitol-fermenting
Escherichia coli O157:NM. FEMS Microbiol Lett. 2012;329:102–10.
28. Back E, Svennerholm AM, Holmgren J, Mollby R. Evaluation of a ganglioside
immunosorbent assay for detection of Escherichia coli heat-labile
enterotoxin. J Clin Microbiol. 1979;10:791–5.
29. Brian MJ, Frosolono M, Murray BE, Miranda A, Lopez EL, Gomez HF, et al.
Polymerase chain reaction for diagnosis of enterohemorrhagic Escherichia
coli infection and hemolytic-uremic syndrome. J Clin Microbiol.
1992;30:1801–6.
30. Gannon VP, Rashed M, King RK, Thomas EJ. Detection and characterization
of the eae gene of Shiga-like toxin-producing Escherichia coli using
polymerase chain reaction. J Clin Microbiol. 1993;31:1268–74.
31. Wang G, Clark CG, Rodgers FG. Detection in Escherichia coli of the genes
encoding the major virulence factors, the genes defining the O157:H7
serotype, and components of the type 2 Shiga toxin family by multiplex
PCR. J Clin Microbiol. 2002;40:3613–9.
32. Brandal LT, Lindstedt BA, Aas L, Stavnes TL, Lassen J, Kapperud G. Octaplex
PCR and fluorescence-based capillary electrophoresis for identification of
human diarrheagenic Escherichia coli and Shigella spp. J Microbiol
Methods. 2007;68:331–41.
33. Brandal LT, Sekse C, Lindstedt BA, Sunde M, Lobersli I, Urdahl AM, et al.
Norwegian sheep are an important reservoir for human-pathogenic
Escherichia coli O26:H11. Appl Environ Microbiol. 2012;78:4083–91.
34. Toma C, Lu Y, Higa N, Nakasone N, Chinen I, Baschkier A, et al. Multiplex
PCR assay for identification of human diarrheagenic Escherichia coli. J Clin
Microbiol. 2003;41:2669–71.
35. Bolin I, Wiklund G, Qadri F, Torres O, Bourgeois AL, Savarino S, et al.
Enterotoxigenic Escherichia coli with STh and STp genotypes is associated
with diarrhea both in children in areas of endemicity and in travelers. J Clin
Microbiol. 2006;44:3872–7.
36. Russmann H, Schmidt H, Heesemann J, Caprioli A, Karch H. Variants of
Shiga-like toxin II constitute a major toxin component in Escherichia coli
O157 strains from patients with haemolytic uraemic syndrome. J Med
Microbiol. 1994;40:338–43.
37. Jelacic JK, Damrow T, Chen GS, Jelacic S, Bielaszewska M, Ciol M, et al.
Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and
clinical profiles. J Infect Dis. 2003;188:719–29.
38. Zheng J, Cui S, Teel LD, Zhao S, Singh R, O'Brien AD, et al. Identification
and characterization of Shiga toxin type 2 variants in Escherichia coli
isolates from animals, food, and humans. Appl Environ Microbiol.
2008;74:5645–52.
39. Lindstedt BA, Heir E, Gjernes E, Vardund T, Kapperud G. DNA fingerprinting
of Shiga-toxin producing Escherichia coli O157 based on Multiple-Locus
Variable-Number Tandem-Repeats Analysis (MLVA). Ann Clin Microbiol
Antimicrob. 2003;2:12.
Brandal et al. BMC Infectious Diseases  (2015) 15:324 Page 9 of 10
40. Lindstedt BA, Brandal LT, Aas L, Vardund T, Kapperud G. Study of
polymorphic variable-number of tandem repeats loci in the ECOR
collection and in a set of pathogenic Escherichia coli and Shigella isolates
for use in a genotyping assay. J Microbiol Methods. 2007;69:197–205.
41. Lobersli I, Haugum K, Lindstedt BA. Rapid and high resolution genotyping
of all Escherichia coli serotypes using 10 genomic repeat-containing loci.
J Microbiol Methods. 2012;88:134–9.
42. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994;309:102.
43. Byrne L, Vanstone GL, Perry NT, Launders N, Adak GK, Godbole G, et al. The
epidemiology and microbiology of Shiga-toxin producing Escherichia coli
other than serogroup O157 in England 2009–2013. J Med Microbiol.
2014;63:1181–8.
44. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL.
Associations between virulence factors of Shiga toxin-producing Escherichia
coli and disease in humans. J Clin Microbiol. 1999;37:497–503.
45. Bielaszewska M, Middendorf B, Kock R, Friedrich AW, Fruth A, Karch H, et al.
Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical
associations with bacterial phylogeny and virulence traits and inferred
in-host pathogen evolution. Clin Infect Dis. 2008;47:208–17.
46. Bielaszewska M, Zhang W, Tarr PI, Sonntag AK, Karch H. Molecular profiling
and phenotype analysis of Escherichia coli O26:H11 and O26:NM: secular
and geographic consistency of enterohemorrhagic and enteropathogenic
isolates. J Clin Microbiol. 2005;43:4225–8.
47. Pradel N, Bertin Y, Martin C, Livrelli V. Molecular analysis of shiga toxin-
producing Escherichia coli strains isolated from hemolytic-uremic
syndrome patients and dairy samples in France. Appl Environ Microbiol.
2008;74:2118–28.
48. Kawano K, Ono H, Iwashita O, Kurogi M, Haga T, Maeda K, et al. stx
genotype and molecular epidemiological analyses of Shiga toxin-producing
Escherichia coli O157:H7/H- in human and cattle isolates. Eur J Clin
Microbiol Infect Dis. 2012;31:119–27.
49. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Wurzner R. The Shiga toxin
genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga
toxin in vitro correlates with the appearance of the hemolytic uremic
syndrome. Diagn Microbiol Infect Dis. 2007;59:235–42.
50. Luna-Gierke RE, Griffin PM, Gould LH, Herman K, Bopp CA, Strockbine N, et
al. Outbreaks of non-O157 Shiga toxin-producing Escherichia coli
infection: USA. Epidemiol Infect. 2014;1–11.
51. Watahiki M, Isobe J, Kimata K, Shima T, Kanatani J, Shimizu M, et al.
Characterization of enterohemorrhagic Escherichia coli O111 and O157
strains isolated from outbreak patients in Japan. J Clin Microbiol.
2014;52:2757–63.
52. Rivero MA, Passucci JA, Rodriguez EM, Parma AE. Role and clinical course of
verotoxigenic Escherichia coli infections in childhood acute diarrhoea in
Argentina. J Med Microbiol. 2010;59:345–52.
53. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in
human medicine. Int J Med Microbiol. 2005;295:405–18.
54. Alpers K, Werber D, Frank C, Koch J, Friedrich AW, Karch H, et al. Sorbitol-
fermenting enterohaemorrhagic Escherichia coli O157:H- causes another
outbreak of haemolytic uraemic syndrome in children. Epidemiol Infect.
2009;137:389–95.
55. Rosser T, Dransfield T, Allison L, Hanson M, Holden N, Evans J, et al.
Pathogenic potential of emergent sorbitol-fermenting Escherichia coli
O157:NM. Infect Immun. 2008;76:5598–607.
56. Nygård K VL, Heier BT, Bruun T, Kapperud G: Annual report: Foodborne
infections and outbreaks in 2009. Reporting system for infectious diseases
(MSIS) and web-based system for outbreak warning (Vesuv). 2010
[In Norwegian], [http://www.fhi.no/eway/default.aspx?pid = 239&trg =
Content_6466&Main_6157 = 6263:0:25,6493&MainContent_6263 =
6466:0:25,6494&Content_6466 = 6259:84108::0:6184:2:::0:0]
57. Preussel K, Hohle M, Stark K, Werber D. Shiga toxin-producing Escherichia
coli O157 is more likely to lead to hospitalization and death than non-O157
serogroups–except O104. PLoS One. 2013;8:e78180.
58. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical
course and the role of shiga toxin-producing Escherichia coli infection in
the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in
Germany and Austria: a prospective study. J Infect Dis. 2002;186:493–500.
59. Pradel N, Livrelli V, De Champs C, Palcoux JB, Reynaud A, Scheutz F, et al.
Prevalence and characterization of Shiga toxin-producing Escherichia coli
isolated from cattle, food, and children during a one-year prospective study
in France. J Clin Microbiol. 2000;38:1023–31.
60. Blanco JE, Blanco M, Alonso MP, Mora A, Dahbi G, Coira MA, et al.
Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-
producing Escherichia coli isolates from human patients: prevalence in
Lugo, Spain, from 1992 through 1999. J Clin Microbiol. 2004;42:311–9.
61. Mingle LA, Garcia DL, Root TP, Halse TA, Quinlan TM, Armstrong LR, et al.
Enhanced identification and characterization of non-O157 Shiga toxin-
producing Escherichia coli: a six-year study. Foodborne Pathog Dis.
2012;9:1028–36.
62. Kappeli U, Hachler H, Giezendanner N, Cheasty T, Stephan R: Shiga toxin-
producing Escherichia coli O157 associated with human infections in
Switzerland, 2000–2009. Epidemiol Infect 2010:1–8.
63. Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, et al.
Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia
coli infections in Minnesota, 2000–2006. Clin Infect Dis. 2009;49:358–64.
64. Statens Serum Institut: Diaréfremkaldende E. coli 2000–2012. EPI-NYT 2014,
[In Danish], [http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2014/
Uge%2010%20-%202014.aspx]
65. Smith JL, Fratamico PM, Gunther NW. Shiga toxin-producing Escherichia
coli. Adv Appl Microbiol. 2014;86:145–97.
66. Vold L, Klungseth Johansen B, Kruse H, Skjerve E, Wasteson Y. Occurrence of
shigatoxinogenic Escherichia coli O157 in Norwegian cattle herds.
Epidemiol Infect. 1998;120:21–8.
67. LeJeune JT, Hancock D, Wasteson Y, Skjerve E, Urdahl AM. Comparison of E.
coli O157 and Shiga toxin-encoding genes (stx) prevalence between Ohio,
USA and Norwegian dairy cattle. Int J Food Microbiol. 2006;109:19–24.
68. Urdahl AM, Beutin L, Skjerve E, Wasteson Y. Serotypes and virulence factors
of Shiga toxin-producing Escherichia coli isolated from healthy Norwegian
sheep. J Appl Microbiol. 2002;93:1026–33.
69. Urdahl AM, Bruheim T, Cudjoe K, Hofshagen M, Hopp P, Johanessen G,
Sunde M: Survey of E. coli in sheep. Veterinærinstituttets rapportserie 2009,
02, [In Norwegian], [http://www.vetinst.no/Publikasjoner/Rapportserie/
Rapportserie-2009/2-2009-Kartlegging-av-E.-coli-hos-sau-resultater-fra-
proever-samlet-inn-i-2007]
70. Werber D, Behnke SC, Fruth A, Merle R, Menzler S, Glaser S, et al. Shiga
toxin-producing Escherichia coli infection in Germany: different risk factors
for different age groups. Am J Epidemiol. 2007;165:425–34.
71. Schimmer B, Nygard K, Eriksen HM, Lassen J, Lindstedt BA, Brandal LT, et al.
Outbreak of haemolytic uraemic syndrome in Norway caused by stx2-
positive Escherichia coli O103:H25 traced to cured mutton sausages.
BMC Infect Dis. 2008;8:41.
72. Wahl E, Vold L, Lindstedt BA, Bruheim T, Afset JE. Investigation of an
Escherichia coli O145 outbreak in a child day-care centre–extensive
sampling and characterization of eae- and stx1-positive E. coli yields
epidemiological and socioeconomic insight. BMC Infect Dis. 2011;11:238.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brandal et al. BMC Infectious Diseases  (2015) 15:324 Page 10 of 10
